Terms: = Endocrine gland cancer AND BRIP1, MGC126521, 83990, ENSG00000136492, FANCJ, FLJ90232, Q9BX63, MGC126523, OF AND Prognosis
216 results:
1. Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer.
Chen L; Fan T; Wang M; Zhu CY; Feng WY; Li Y; Yang H
Expert Opin Ther Targets; 2024; 28(1-2):83-95. PubMed ID: 38235574
[TBL] [Abstract] [Full Text] [Related]
2. Pathology and new insights in thyroid neoplasms in the 2022 WHO classification.
Lebrun L; Salmon I
Curr Opin Oncol; 2024 Jan; 36(1):13-21. PubMed ID: 37975316
[TBL] [Abstract] [Full Text] [Related]
3. Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
Yuan D; Zhu H; Wang T; Zhang Y; Zheng X; Qu Y
Eur J Med Res; 2023 Oct; 28(1):465. PubMed ID: 37884970
[TBL] [Abstract] [Full Text] [Related]
4. High-grade serous ovarian carcinoma, the "Achiles' hill" for clinicians and molecular biologists: a molecular insight.
Bhattacharya R; Ghosh A; Mukhopadhyay S
Mol Biol Rep; 2023 Nov; 50(11):9511-9519. PubMed ID: 37737967
[TBL] [Abstract] [Full Text] [Related]
5. Current limits of conservative treatment in ovarian cancer.
Gracia M; Alonso-Espías M; Zapardiel I
Curr Opin Oncol; 2023 Sep; 35(5):389-393. PubMed ID: 37498109
[TBL] [Abstract] [Full Text] [Related]
6. Thyroid lymphoma.
Rovira A; Carroll P; Simo R
Curr Opin Otolaryngol Head Neck Surg; 2023 Apr; 31(2):83-88. PubMed ID: 36912220
[TBL] [Abstract] [Full Text] [Related]
7. Complementary and Integrative Medicine in Pancreatic cancer.
Frenkel M; David A; Sapire K; Hausner D
Curr Oncol Rep; 2023 Mar; 25(3):231-242. PubMed ID: 36735141
[TBL] [Abstract] [Full Text] [Related]
8. A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?
Su J; Lu J; Zhang J; Wang M; Yan J; Lin S
Curr Opin Oncol; 2023 Mar; 35(2):132-144. PubMed ID: 36721897
[TBL] [Abstract] [Full Text] [Related]
9. Other markers of medullary thyroid cancer, not only calcitonin.
Censi S; Manso J; Mian C
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651167
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic Markers after Hepatic Function Impairment in Patients with Pancreatic Adenocarcinoma.
Buyukkor M; Tay F; Karacin C; Duran AO
J Coll Physicians Surg Pak; 2023 Jan; 33(1):32-36. PubMed ID: 36597232
[TBL] [Abstract] [Full Text] [Related]
11. Liposome-based diagnostic and therapeutic applications for pancreatic cancer.
Raza F; Evans L; Motallebi M; Zafar H; Pereira-Silva M; Saleem K; Peixoto D; Rahdar A; Sharifi E; Veiga F; Hoskins C; Paiva-Santos AC
Acta Biomater; 2023 Feb; 157():1-23. PubMed ID: 36521673
[TBL] [Abstract] [Full Text] [Related]
12. Oligometastatic disease from differentiated thyroid cancer: best treatment schemes.
Colombo E; Ottini A; Licitra L
Curr Opin Oncol; 2023 Jan; 35(1):15-21. PubMed ID: 36475458
[TBL] [Abstract] [Full Text] [Related]
13. Clinical Significance of Methyltransferase-like 16 Expression in Epithelial Ovarian cancer.
Li C; Qiao C; Ding H; Luo Y
J Coll Physicians Surg Pak; 2022 Dec; 32(12):1576-1580. PubMed ID: 36474378
[TBL] [Abstract] [Full Text] [Related]
14. Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.
Brönimann S; Garstka N; Remzi M
Curr Opin Urol; 2023 Jan; 33(1):50-58. PubMed ID: 36444650
[TBL] [Abstract] [Full Text] [Related]
15. Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy.
Jungels C; Pita JM; Costante G
Curr Opin Oncol; 2023 Jan; 35(1):1-9. PubMed ID: 36398690
[TBL] [Abstract] [Full Text] [Related]
16. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract] [Full Text] [Related]
17. Advanced imaging and theranostics in thyroid cancer.
Roseland ME; Dewaraja YK; Wong KK
Curr Opin Endocrinol Diabetes Obes; 2022 Oct; 29(5):456-465. PubMed ID: 36068937
[TBL] [Abstract] [Full Text] [Related]
18. [Évolution des traitements adjuvants des cancers de l'ovaire].
Pautier P
Rev Prat; 2022 Jun; 72(6):633-637. PubMed ID: 35899664
[TBL] [Abstract] [Full Text] [Related]
19. MANAGEMENT OF endocrine DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
Saltiki K; Simeakis G; Karapanou O; Alevizaki M
Eur J Endocrinol; 2022 Sep; 187(3):R53-R63. PubMed ID: 35895692
[TBL] [Abstract] [Full Text] [Related]
20. Use of staging for sex cord stromal tumours.
Negri S; Grassi T; Fruscio R
Curr Opin Oncol; 2022 Sep; 34(5):504-510. PubMed ID: 35849655
[TBL] [Abstract] [Full Text] [Related]
[Next]
